|
Sex
|
Male
|
200
|
(55.7)
|
|
Female
|
158
|
(44.0)
|
|
No response
|
1
|
(0.3)
|
|
Pharmacy experience, years
|
1 to 3
|
8
|
(2.2)
|
|
4 to 6
|
42
|
(11.7)
|
|
7 to 9
|
44
|
(12.3)
|
|
10 to 14
|
94
|
(26.2)
|
|
15 to 19
|
65
|
(18.1)
|
|
more than 19
|
105
|
(29.2)
|
|
No response
|
1
|
(0.3)
|
|
Receives “Total drug evaluation and management healthcare reimbursement fee”
|
| |
Yes
|
176
|
(49.0)
|
|
No
|
183
|
(51.0)
|
|
Board pharmacy certification
|
Yes
|
222
|
(61.8)
|
|
No
|
130
|
(36.2)
|
|
No response
|
7
|
(1.9)
|
|
BCPPP1)
|
123
|
(34.3)
|
|
BCPOP2)
|
82
|
(22.8)
|
|
JSPHCS3) certification of Oncology Pharmacist
|
52
|
(14.5)
|
|
APACC4)
|
32
|
(8.9)
|
|
Pharmacists with certifications other than BCPPP
|
99
|
(27.6)
|
|
Confidence score in palliative care (No confidence, 0; full confidence, 10)
|
| |
Zero
|
5
|
(1.4)
|
|
1
|
7
|
(1.9)
|
|
2
|
5
|
(1.4)
|
|
3
|
9
|
(2.5)
|
|
4
|
10
|
(2.8)
|
|
5
|
54
|
(15.0)
|
|
6
|
76
|
(21.2)
|
|
7
|
92
|
(25.6)
|
|
8
|
69
|
(19.2)
|
|
9
|
24
|
(6.7)
|
|
10
|
8
|
(2.2)
|
|
Nationwide attendance at continuing education sessions related to palliative care in a year
|
| |
Zero
|
17
|
(4.7)
|
|
1 to 3
|
260
|
(72.4)
|
|
4 to 6
|
58
|
(16.2)
|
|
7 to 9
|
14
|
(3.9)
|
|
More than 9
|
10
|
(2.8)
|
|
Percentage of cancer patients managed by pharmacists
|
| |
Zero
|
7
|
(1.9)
|
|
1 to 39%
|
97
|
(27.0)
|
|
40 to 69%
|
94
|
(26.2)
|
|
70 to 99%
|
103
|
(28.7)
|
|
100%
|
58
|
(16.2)
|
